The new NICE guidance for type 2 diabetes -- was it worth the wait?

ENZYME inhibitors; HYPOGLYCEMIC agents; SULFONYLUREAS; METFORMIN; PIOGLITAZONE; GLUCAGON-like peptide-1 agonists; BLOOD sugar monitoring; CARDIOVASCULAR diseases risk factors; COMBINATION drug therapy; DIABETES; FAMILY medicine; GLYCOSYLATED hemoglobin; MEDICAL office nursing; MEDICAL protocols; TYPE 2 diabetes; PATIENT education; HEALTH self-care; WORLD Wide Web; INFORMATION resources; BODY mass index; PATIENT-centered care; SODIUM-glucose cotransporters; THERAPEUTICS

The article offers information on the guidelines issued by the non-departmental public organization National Institute for Health and Care Excellence (NICE)for managing type 2 diabetes. Topics include the administration of metformin as an oral hypoglycemic agent, management of home blood glucose monitoring (HBGM), and the management of cardiovascular disease (CVD) risk.